ImmunityBio, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Congresswoman Lisa McClain reported stock transactions, including purchases of CACI International (NYSE:CACI) and Microsoft (NASDAQ:MSFT) valued between $15,001 and $50,000. CACI, a defense contractor, has a market cap of $13.6B and a 20% return over the past year. McClain also invested in several other stocks and partially sold Seagate Technology (NASDAQ:STX) shares.
Cohen Cheryl sold 81,056 shares of ImmunityBio, Inc. (IBRX) at $10.50 ($0.85M total) on 2026-10-02 under a Rule 10b5-1 trading plan.
Novavax (NVAX), Moderna (MRNA), Emergent BioSolutions (EBS), and Arcturus Therapeutics (ARCT) surged 20%, 7%, 14%, and 13% respectively, following a Russian lab worker's death. Retail investors speculated about potential government contracts. Other related stocks like Alpha Pro Tech (APT), Lakeland Industries (LAKE), and NanoViricides (NNVC) also rose. The WHO and U.S. officials downplayed the risk, but traders anticipated increased preparedness spending.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning IBRX (ImmunityBio, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent IBRX coverage spans market movers, financial news and insider activity.
In the last 30 days, IBRX insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($1.1M). The most active reporter was Simon Barry J. with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Small buy may be noted by biotech traders.
The insider sale may signal limited confidence and could weigh on the stock.
Minimal impact; slight positive bias.
The appointment is seen as a catalyst for broader Anktiva access, supporting short-term upside.
Institutional buying pressure likely supports further upside.
AlphAI scores every news story that mentions IBRX with an AI model for sentiment and relevance, and aggregates insider trades from ImmunityBio, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Congresswoman Lisa McClain reported stock transactions, including purchases of CACI International (NYSE:CACI) and Microsoft (NASDAQ:MSFT) valued between $15,001 and $50,000. CACI, a defense contractor, has a market cap of $13.6B and a 20% return over the past year. McClain also invested in several other stocks and partially sold Seagate Technology (NASDAQ:STX) shares.
2 min readCohen Cheryl sold 81,056 shares of ImmunityBio, Inc. (IBRX) at $10.50 ($0.85M total) on 2026-10-02 under a Rule 10b5-1 trading plan.
1 min readNovavax (NVAX), Moderna (MRNA), Emergent BioSolutions (EBS), and Arcturus Therapeutics (ARCT) surged 20%, 7%, 14%, and 13% respectively, following a Russian lab worker's death. Retail investors speculated about potential government contracts. Other related stocks like Alpha Pro Tech (APT), Lakeland Industries (LAKE), and NanoViricides (NNVC) also rose. The WHO and U.S. officials downplayed the risk, but traders anticipated increased preparedness spending.
2 min readImmunityBio (IBRX) shares rose 22% last week, the best performance in over seven months, following Michael Caputo's appointment to Trump's Cancer Panel. The company's founder, Patrick Soon-Shiong, highlighted advancements in cancer immunotherapy. IBRX seeks FDA approval for Anktiva's expanded use in bladder cancer by January 2027, with recent data showing 58.2% disease-free survival at 12 months.
2 min readImmunityBio (IBRX) shares rose 7% to $9.44, a seven-month high, after Q3 filings showed BlackRock and Vanguard increased holdings. BlackRock added 7.74M shares, narrowing Vanguard's lead. Other institutional investors, like Two Sigma, also boosted stakes. FDA decision and tokenization plans are pending.
2 min readImmunityBio Inc. shares rose 11.44% to $9.84 on Wednesday, driven by investor optimism around its bladder cancer drug Anktiva and an upcoming FDA decision. The company reported record Q2 2026 revenue of $50.7M, up 92% YoY, but posted a loss of 22 cents per share. Anktiva's expanded use and international approvals are key growth drivers.
2 min readImmunityBio (IBRX) shares rose 1% in overnight trading after CEO Richard Adcock announced the company's Dunkirk manufacturing project for its cancer immunotherapy, Anktiva, is now moving forward. The project, which faced delays due to contractor bankruptcy, has received unanimous approval from local officials. ImmunityBio has invested over $100 million and plans to deploy more funds.
2 min readImmunityBio (IBRX) shares rose 9.94% to $9.29 after its founder met with Turkish President Erdogan, sparking expansion hopes. The company's Anktiva drug, approved in 34 countries, drove Q2 revenue to $51.24M, up 94% YoY, though net loss widened to $230.39M. Hedge fund holdings increased 62.6% QoQ to $314.9M.
2 min readImmunityBio (IBRX) shares rose after founder Patrick Soon-Shiong hinted at tokenizing stocks via Nant's blockchain platform. Soon-Shiong, who owns 65.5% of IBRX, cited the SEC's new framework for tokenized securities. Retail traders speculated about potential tokenization of IBRX and PDS Biotechnology (PDSB), with IBRX up 328% year-to-date.
2 min readJohnson & Johnson and Pfizer are targeting early-stage cancer assets, focusing on Sellas Life Sciences (SLS), ImmunityBio (IBRX), and Iovance Biotherapeutics (IOVA). SLS's SLS009 showed 46%-50% response rates in AML, while Iovance expects lung-cancer data in Q4. J&J's CEO highlighted M&A interest in early-stage opportunities, with recent deals like Halda Therapeutics and Firefly Bio. IOVA, IBRX, and SLS stocks rose 8%, 6%, and 2% respectively on Monday.
2 min read
